Global Cancer News

FDA Approves Trodelvy (Sacituzumab govitecan-hziy) for Triple Negative Breast Cancer


The US Food and Drug Administration (FDA) approved a new type of therapy for triple-negative breast cancer that has spread to other parts of the body and hasn’t responded to other treatments. Triple-negative breast cancer is called that because the cancer cells don’t have estrogen or progesterone receptors and also don’t make too much of the protein called HER2. It has few treatment options and tends to grow and spread faster than other types of breast cancer.

See full information at: